Patent Application
20220226106
This document relates to prosthetic heart valves, such as prosthetic mitral valves that can be implanted using transcatheter techniques. This document also relates to systems and methods for implanting composite prosthetic mitral valves having an inner valve portion that is affixed to an outer anchor portion.
The long-term clinical effect of valve regurgitation is recognized as a significant contributor to cardiovascular related morbidity and mortality. Thus, for many therapies intended to treat the mitral valve, one primary goal is to significantly reduce or eliminate regurgitation. By eliminating the regurgitation at the mitral valve, the destructive volume overload effects on the left ventricle can be attenuated. The volume overload of mitral regurgitation (MR) relates to the excessive kinetic energy required during isotonic contraction to generate overall stroke volume in an attempt to maintain forward stroke volume and cardiac output. It also relates to the pressure potential energy dissipation of the leaking valve during the most energy-consuming portion of the cardiac cycle, isovolumetric contraction. Additionally, therapies for MR reduction can have the effect of reducing the elevated pressures in the left atrium and pulmonary vasculature reducing pulmonary edema (congestion) and shortness of breath symptomatology. Such therapies for MR reduction may also have a positive effect on the filling profile of the left ventricle (LV) and the restrictive LV physiology that can result with MR. These pathophysiologic issues indicate the potential benefits of MR therapy, but also indicate the complexity of the system and the need for a therapy to focus beyond the MR level or grade.
In some percutaneous access procedures in which a medical device is introduced through a patient's skin and into a patient's blood vessel, such an access can be used to introduce devices into the patient without the use of large cut downs, which can be painful and in some cases can hemorrhage or become infected. A percutaneous access generally employs only a small hole through the skin, which subsequently seals relatively easily, and heals quickly in comparison to a surgical cut down.
This document describes prosthetic heart valves, such as prosthetic mitral valves, that interface and anchor in cooperation with the anatomical structures of a native mitral valve. For example, this document describes a composite two-portion prosthetic heart valve in which two expandable components are attached to each other and arranged in a nested configuration during both the transcatheter delivery process and the deployment process within the heart. In addition, systems and methods for implanting such composite two-portion prosthetic heart valves are described herein.
In one aspect, this disclosure is directed to a prosthetic mitral valve for a heart. The prosthetic mitral valve includes a valve assembly comprising an expandable valve frame and an occluder attached to the expandable valve frame, and an anchor assembly comprising an expandable anchor frame. The valve assembly is disposed within an interior space defined by the anchor assembly.
Such a prosthetic mitral valve may optionally include one or more of the following features. In some embodiments, the expandable valve frame includes three atrial leaflet arches disposed on a proximal end portion of the expandable valve frame. In particular embodiments, the expandable anchor frame includes three anchor arches disposed on a proximal end portion of the expandable anchor frame. In certain embodiments, each atrial leaflet arch of the three atrial leaflet arches is affixed to a respective anchor arch of the three anchor arches.
In another aspect, this disclosure is directed to a prosthetic mitral valve that includes: (i) a valve assembly comprising an expandable valve frame and an occluder attached to the expandable valve frame, the expandable valve frame comprising three atrial leaflet arches disposed on a proximal end portion of the expandable valve frame; and (ii) an anchor assembly comprising an expandable anchor frame, the expandable anchor frame comprising three anchor arches disposed on a proximal end portion of the expandable anchor frame. The valve assembly is disposed within an interior space defined by the anchor assembly. Each atrial leaflet arch of the three atrial leaflet arches is affixed to a respective anchor arch of the three anchor arches.
Such a prosthetic mitral valve may optionally include one or more of the following features. An apex portion of each atrial leaflet arch of the three atrial leaflet arches may be affixed to an apex portion of the respective anchor arch of the three anchor arches. An entirety of each atrial leaflet arch of the three atrial leaflet arches may be affixed to an entirety of the respective anchor arch of the three anchor arches. The expandable anchor frame may also include a plurality of arched atrial holding features. In some embodiments, while the expandable anchor frame is in an expanded configuration, each arched atrial holding feature of the plurality of arched atrial holding features extends transversely outward in relation to a longitudinal axis defined by the anchor assembly. The plurality of arched atrial holding features may include three arched atrial holding features. Each arched atrial holding feature of the three arched atrial holding features may be aligned with a corresponding atrial leaflet arch of the three atrial leaflet arches and with a corresponding atrial leaflet arch of the three atrial leaflet arches. In some embodiments, while the prosthetic mitral valve is coupled to a native mitral valve, each arched atrial holding feature of the plurality of arched atrial holding features is positioned directly adjacent to, or spaced apart just superior to, an annulus of the native mitral valve. The expandable anchor frame may also include: (a) a hub; (b) a first elongate element extending from the hub, the first elongate element including a first sub-annular foot; (c) a second elongate element extending from the hub, the second elongate element including a second sub-annular foot; (d) a third elongate element extending from the first elongate element, the third elongate element including a third sub-annular foot; and (e) a fourth elongate element extending from the second elongate element, the fourth elongate element including a fourth sub-annular foot. In some embodiments, while the anchor assembly is coupled to a native mitral valve, each of the first foot, the second foot, the third foot, and the fourth foot are positioned within a sub-annular gutter of the native mitral valve. The hub may be located at a distal end of the expandable anchor frame and may be threaded for releasable attachment with a delivery device. The expandable anchor frame may also include a systolic anterior motion containment member that is configured to be at least partially disposed behind an anterior leaflet of the native mitral valve while the anchor assembly is coupled to the native mitral valve.
In another aspect, this disclosure is directed to a prosthetic mitral valve that includes: (1) a valve assembly comprising an expandable valve frame and an occluder attached to the expandable valve frame, the expandable valve frame being expandable from a compressed nested configuration during transcatheter delivery to a deployed configuration at a native mitral heart valve site; and (2) an anchor assembly comprising an expandable anchor frame. The expandable anchor frame being expandable from a compressed delivery configuration during transcatheter delivery to an anchored configuration at a native mitral heart valve site. The expandable valve frame of the valve assembly is nested within the expandable anchor frame anchor while the expandable anchor frame is in the compressed delivery configuration for transcatheter delivery.
In another aspect, this disclosure is directed to a transcatheter mitral valve replacement system for a heart, that includes: (i) a delivery sheath having a distal end portion insertable into a left atrium; (ii) a delivery catheter slidably disposed within the delivery sheath; and (iii) a composite two-portion prosthetic mitral valve coupled to the delivery catheter by one or more control wires. The composite two-portion prosthetic mitral valve is configured to be disposed within the delivery sheath in a radially compressed condition and to radially self-expand when the composite two-portion prosthetic mitral valve is outside of the delivery sheath and is unconstrained by the one or more control wires. The composite two-portion prosthetic mitral valve includes: (a) a valve assembly including an expandable valve frame and a tri-leaflet occluder, the expandable valve frame comprising three atrial leaflet arches disposed on a proximal end portion of the expandable valve frame; and (b) an anchor assembly comprising an expandable anchor frame that defines an interior space within which the valve assembly is nested. The expandable anchor frame comprising three anchor arches disposed on a proximal end portion of the expandable anchor frame. Each atrial leaflet arch of the three atrial leaflet arches is affixed to a respective anchor arch of the three anchor arches.
Such a transcatheter mitral valve replacement system may optionally include one or more of the following features. The system may also include a pusher catheter slidably disposed within the deliver catheter and releasably coupled to the anchor assembly. The one or more control wires may include: a first control wire coupled to proximal end portions of the anchor assembly and the valve assembly; a second control wire coupled to a mid-body portion of the anchor assembly; and a third control wire coupled to a distal end portion of the valve assembly. The one or more control wires comprises a total of two control wires consisting of: a first control wire coupled to proximal end portions of the anchor assembly and the valve assembly; and a second control wire coupled to a distal end portion of the valve assembly. The one or more control wires comprises a total of two control wires consisting of: a first control wire coupled to proximal end portions of the anchor assembly and the valve assembly; and a second control wire coupled to a mid-body portion of the anchor assembly.
In another aspect, this disclosure is directed to a method for deploying a transcatheter prosthetic mitral valve system within a native mitral valve of a patient. The method includes: (a) navigating a delivery sheath within a vasculature of the patient such that a distal end portion of the delivery sheath is positioned within a left atrium of the patient, the delivery sheath containing a composite two-portion prosthetic mitral valve in a radially compressed condition. The composite two-portion prosthetic mitral valve includes: (i) a valve assembly including an expandable valve frame and a tri-leaflet occluder, the expandable valve frame comprising three atrial leaflet arches disposed on a proximal end portion of the expandable valve frame; and (ii) an anchor assembly comprising an expandable anchor frame that defines an interior space within which the valve assembly is nested, the expandable anchor frame comprising three anchor arches disposed on a proximal end portion of the expandable anchor frame. Each atrial leaflet arch of the three atrial leaflet arches is affixed to a respective anchor arch of the three anchor arches. The method for deploying a transcatheter prosthetic mitral valve system within a native mitral valve of a patient further includes: (b) expressing, in the left atrium, the composite two-portion prosthetic mitral valve, wherein a delivery catheter is releasably engaged with the composite two-portion prosthetic mitral valve using one or more control wires, the valve assembly remaining disposed within the interior space defined by the anchor assembly during and after the expressing; (b) engaging the anchor assembly with the native mitral valve, wherein the anchor assembly is in a radially expanded condition while engaged with the native mitral valve; and (c) after the engaging the anchor assembly in the radially expanded condition, expanding a distal end portion of the expandable valve frame within the interior space.
In some embodiments of the method for deploying a transcatheter prosthetic mitral valve system within a native mitral valve of a patient, the engaging the anchor assembly with the native mitral valve includes positioning atrial holding features of the anchor assembly adjacent to supra-annular tissue surfaces above an annulus of the mitral valve.
In another aspect, this disclosure is directed to a prosthetic mitral valve that includes: (1) a valve assembly comprising a plurality of atrial leaflet arches disposed on a proximal end portion of the valve assembly and one or more valve leaflets; and (2) an anchor assembly comprising a plurality of anchor arches disposed on a proximal end portion of the anchor assembly. The valve assembly is disposed within an interior space defined by the anchor assembly. Each atrial leaflet arch of the plurality of atrial leaflet arches is affixed to a respective anchor arch of the plurality of anchor arches.
In another aspect, this disclosure is directed to a prosthetic mitral valve that includes: a valve assembly comprising a plurality of valve leaflets; and an anchor assembly. The valve assembly is disposed within an interior space defined by the anchor assembly. A proximal end of the valve assembly is affixed to a proximal end of the anchor assembly.
Some or all of the embodiments described herein may provide one or more of the following advantages. First, using the devices, systems, and methods in accordance with particular implementations described herein, various medical conditions, such as heart valve conditions, can be treated in a minimally invasive fashion. Such minimally invasive techniques can tend to reduce recovery times, patient discomfort, and treatment costs.
Second, some implementations of the devices, systems, and methods described herein facilitate the implantation of a composite two-portion prosthetic heart valve in which two expandable components are attached and arranged in a nested configuration during the transcatheter delivery and deployment processes. Accordingly, the time to complete the procedure is advantageously minimalized. This can result in reduced time in the operating room, lessened patient risks, and lower procedural costs.
Third, the transcatheter prosthetic heart valve and deployment systems described herein can be configured to facilitate accurate control of the prosthetic valve components during the delivery and deployment process. In some embodiments, one or more control wires are coupled to end portions or middle portions of the prosthetic valve components in a manner that allows for isolated, accurate movements of each degree of freedom associated with the catheters and prosthetic valve components. Accordingly, relatively complex catheter and/or valve component movements are facilitated in an accurately controllable and user-convenient manner. In result, transcatheter implant procedures can be performed with enhanced patient safety and treatment efficacy using the devices, systems, and methods described herein.
Fourth, some embodiments of the prosthetic mitral valve and deployment systems described herein can be used in a completely percutaneous/transcatheter mitral replacement procedure that is streamlined, safe, reliable, and repeatable by surgeons and/or interventional cardiologists of a variety of different skill levels.
Fifth, in particular embodiments, the composite two-portion prosthetic mitral valves can optionally include two different expandable components (e.g., an anchor assembly and a valve assembly) that are delivered to the implantation site in an attached and nested arrangement. For example, the first component (e.g., the anchor assembly including a first expandable frame) can be configured to engage with the heart tissue that is at or proximate to the annulus of the native mitral valve, and the second component (e.g., the valve assembly including a second expandable frame) can be configured to provide a seal interface with native valve leaflets of the mitral valve.
Sixth, by using particular implementations of the composite two-portion prosthetic heart valves that are attached and arranged in a nested configuration during the transcatheter delivery and deployment processes, patients can be treated while guarding the patients' hemodynamic stability during the implantation process. Such devices and techniques can tend to reduce the need for ancillary interventions, such as the need for installing a balloon pump and the like.
The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
Like reference symbols in the various drawings indicate like elements.
Referring to
In some embodiments, the two-portion prosthetic mitral valve 400 comprises two separate portions, an anchor assembly portion 200 and a valve assembly portion 300, that can be made to mechanically engage in a releasably mated configuration with each other in situ. In particular embodiments, however, the two-portion prosthetic mitral valve 400 is a single composite structure that includes an anchor assembly portion 200 and a concomitant, conjoined valve assembly portion 300 that are permanently attached to each other. This disclosure is primarily directed to the latter. That is, this disclosure is primarily directed to embodiments of two-portion prosthetic mitral valves 400 that are single composite structures in which at least portions of the anchor assembly portion 200 and the valve assembly portion 300 are permanently conjoined, attached, and/or affixed to each other.
In some implementations, the two-portion prosthetic mitral valve 400 is percutaneously deployed via a femoral or iliac vein through a groin opening/incision 2 in the patient 1 in a minimally invasive fashion. In particular implementations, a deployment control system 6 is used to initiate and/or control the movements of various components of the transcatheter delivery system 100, and of the two-portion prosthetic mitral valve 400.
The two-portion prosthetic mitral valve 400 can be delivered to and implanted in the heart 10 using a percutaneous, or minimally invasive, technique via the venous or arterial system (without open-chest or open-heart surgery). In some implementations, the transcatheter delivery system 100 and two-portion prosthetic mitral valve 400 are used in conjunction with one or more imaging modalities such as x-ray fluoroscopy, echocardiography, magnetic resonance imaging, computed tomography (CT), and the like. Accordingly, various components of the transcatheter delivery system 100 and/or the two-portion prosthetic mitral valve 400 can include one or more features to enhance their visibilities under imaging modalities, such as radio-opaque markers.
Early steps of the process for deploying the two-portion prosthetic mitral valve 400 includes the placement of a guidewire within the vasculature and heart 10 of the patient 1. In the depicted implementation, the guidewire is installed into the heart 10 prior to the other components of the delivery system 100. In some embodiments, the guidewire is made of materials such as, but not limited to, nitinol, stainless steel, high-tensile-strength stainless steel, and the like, and combinations thereof. The guidewire 11 may include various tip designs (e.g., J-tip, straight tip, etc.), tapers, coatings, covers, radiopaque (RO) markers, and other features. In some embodiments, the guidewire has one or more portions with differing lateral stiffnesses, column strengths, lubricity, and/or other physical properties in comparison to other portions of the guidewire.
In some implementations, the guidewire is percutaneously inserted into a femoral vein of the patient 1. The guidewire is routed to the inferior vena cava and into the right atrium. After creating an opening in the atrial septum (e.g., a trans-septal puncture of the fossa ovalis or other portion of the atrial septum), the guidewire is routed into the left atrium 16. Lastly, the guidewire is routed through the native mitral valve 17 and into the left ventricle 18. This is preferably performed without entangling the guidewire with the chordae tendineae 40 of the native mitral valve 17. In some implementations, the guidewire can be installed into the heart 10 along other anatomical pathways. The guidewire thereafter serves as a rail over which other components of the delivery system 100 are passed.
The transcatheter delivery system 100 facilitates implantation of the two-portion prosthetic mitral valve 400 in the heart 10 while the heart 10 is beating. Using interventional cardiology techniques, the transcatheter prosthetic heart valve delivery system 100 can be navigated through the venous vasculature of the patient 1, and through the atrial septum (e.g., a trans-septal puncture of the fossa ovalis or other portion of the atrial septum), to obtain access to the left atrium 16 of the patient's heart 10.
In
In the depicted embodiment, the anchor assembly portion 200 includes four anchor feet: a lateral anterior foot 220a, a lateral posterior foot 220b, a medial posterior foot 220c, and a medial anterior foot 220d. In some embodiments, fewer or more anchor feet may be included (e.g., two, three, five, six, or more than six). In some embodiments, the anchor feet 220a, 220b, 220c, and 220d are portions of the anchor assembly portion 200 that are configured for contact with a sub-annular gutter 19 of the native mitral valve 17, without penetrating tissue of the native mitral valve 17. Accordingly, the anchor feet 220a, 220b, 220c, and 220d have atraumatic surfaces that are generally comparable to feet. However, in some embodiments one or more of the anchor feet 220a, 220b, 220c, and 220d are configured to penetrate tissue and may have anchor features such as barbs, coils, hooks, and the like.
It should be understood that the depicted anchor assembly portion 200 is merely one non-limiting example of the anchor assemblies included within the scope of this disclosure.
In some embodiments, the anchor assembly portion 200 includes supra-annular structures and sub-annular structures (in reference to the positions of those structures in relation to the annulus of the native mitral valve 17 when the two-portion prosthetic mitral valve 400 is implanted at the site of the native mitral valve 17). For example, in some embodiments the sub-annular structures of the anchor assembly portion 200 can include the aforementioned anchor feet 220a, 220b, 220c, and 220d, a systolic anterior motion (SAM) containment member 212, and a hub 210. The SAM containment member 212 is designed to inhibit the incursion of an anterior leaflet of the native mitral valve 17 into the left ventricular outflow tract (LVOT) during systole, which might otherwise cause LVOT obstruction or the creation of high LVOT pressure gradients. In some embodiments, the hub 210 functions as a connection structure for the delivery system 100. In addition, the hub 210 can function as a stabilizing structural component from which a lateral anterior sub-annular support arm 230a and a medial anterior sub-annular support arm 230d extend to the anchor feet 220a and 220d respectively. In some embodiments, a lateral posterior sub-annular support arm 230b extends from the lateral anterior sub-annular support arm 230a to the lateral posterior foot 220b. In some embodiments, a medial posterior sub-annular support arm 230c extends from the medial anterior sub-annular support arm 230d to the medial posterior foot 220c. In particular embodiments, no hub 210 is included.
In the depicted embodiment, the supra-annular structures of the anchor assembly portion 200 include: a lateral anterior atrial holding feature 240a, a posterior atrial holding feature 240b, and a medial anterior atrial holding feature 240c; a lateral anterior anchor arch 250a, a posterior anchor arch 250b, and a medial anterior anchor arch 250c. The atrial holding features 240a, 240b, and 240c are configured to contact the shelf-like supra-annular atrial tissue surface superior to the mitral valve annulus, and to thereby stabilize the two-portion prosthetic mitral valve 400 in supra-annular areas and to provide migration resistance in the inferior direction toward the left ventricle 18.
The lateral anterior anchor arch 250a, the posterior anchor arch 250b, and the medial anterior anchor arch 250c are joined with each other, or unitary with each other, to form an undulating supra-annular ring 250 that acts as a supra-annular structural element to which the valve assembly portion 300 can be affixed.
The valve assembly portion 300 includes a proximal end portion 302 and a distal end portion 303. When the two-portion prosthetic mitral valve 400 is implanted in a native mitral valve 17, the proximal end portion 302 is located supra-annularly (in the left atrium 16, superior to the annulus of the native mitral valve 17) and the distal end portion 303 is located sub-annular (in the left ventricle 18, interior to the annulus of the native mitral valve 17). The proximal end portion 302 defines the generally circular valvular entrance orifice of the valve assembly portion 300. At least three prosthetic valve leaflets (not visible) are located within the valve assembly portion 300.
In the depicted embodiment, the proximal end portion 302 of the valve assembly portion 300 includes three atrial leaflet arches 310a, 310b, and 310c that together define an undulating ring 310 at the proximal end portion 302 of the valve assembly portion 300. The undulating ring 310 formed by the three atrial leaflet arches 310a, 310b, and 310c generally corresponds to the undulating supra-annular ring 250 of the anchor assembly portion 200. Accordingly, as described further below, the anchor assembly portion 200 and the valve assembly portion 300 can be conjoined and/or affixed to each other at particular locations of, or entirely along, the adjacent interfacing portions of the supra-annular ring 250 and the undulating ring 310 of three atrial leaflet arches 310a, 310b, and 310c. In some embodiments, the supra-annular ring 250 of the anchor assembly portion 200 and the undulating ring 310 of the valve assembly portion 300 (or portions thereof) are unitarily formed as a single, shared element (rather than being a conjoined two-piece construct).
In some embodiments, each of the leaflet arches 310a, 310b, and 310c includes an apex having one or more holes 312a, 312b, and 312c respectively. In some embodiments, the holes 312a, 312b, and 312c are used for coupling the proximal end of the valve assembly portion 300 to a delivery catheter using a proximal control wire. In some embodiments, one or more of the holes 312a, 312b, and 312c are used for containing radiopaque material.
In the depicted embodiment, the valve assembly portion 300 generally flares outward along a distal direction. Said differently, the distal end portion 303 is flared outward in comparison to the proximal end portion 302. Accordingly, the proximal end portion 302 defines a smaller outer profile in comparison to the distal end portion 303. However, some regions of the distal end portion 303 bow inwardly. Such inward bowing can serve to mitigate LVOT obstructions and enhance sealing in some cases.
In some embodiments, the periphery of the distal end portion 303 is generally D-shaped in cross-section. The D-shaped periphery of the distal end portion 303 provides the valve assembly portion 300 with an advantageous outer profile for interfacing and sealing with the native mitral valve 17. For example, in some implementations sealing is attained by coaptation between the D-shaped periphery of the distal end portion 303 and the leaflets of the native mitral valve 17.
In some embodiments, such as the depicted embodiment, valve assembly portion 300 includes three leaflets (not visible) that perform the occluding function of the prosthetic mitral valve 400. The cusps of the three leaflets are fixed to the three atrial leaflet arches 310a, 310b, and 310c, and to three commissural posts (not visible) that each extend distally from the intersections of the three leaflet arches 310a, 310b, and 310c. In some embodiments, the three commissural posts are disposed at about 120° apart from each other. The commissural posts each have a series of holes that can be used for attachment of the prosthetic valve leaflets, such as by suturing. The three leaflet arches 310a, 310b, and 310c and the three commissural posts are areas on the valve assembly portion 300 to which the three prosthetic valve leaflets become attached to comprise a tri-leaflet occluder. As such, the valve assembly portion 300 provides a proven and advantageous frame configuration for the tri-leaflet occluder. When implanted in the native mitral valve 17, the tri-leaflet occluder of the valve assembly portion 300 provides open flow during diastole and occlusion of flow during systole. The free edges of the three leaflets can seal by coaptation with each other during systole and open during diastole.
The three leaflets can be comprised of natural or synthetic materials. For example, the three leaflets can be comprised of any of the materials described below in reference to the coverings 270 and/or 340, including the natural tissues such as, but not limited to, bovine, porcine, ovine, or equine pericardium. In some such embodiments, the tissues are chemically cross-linked using glutaraldehyde, formaldehyde, or triglycidyl amine solution, or other suitable crosslinking agents. In some embodiments, the leaflets have a thickness in a range of about 0.005″ to about 0.020″ (about 0.13 mm to about 0.51 mm), or about 0.008″ to about 0.012″ (about 0.20 mm to about 0.31 mm). In some embodiments, the leaflets have a thickness that is less than about 0.005″ (about 0.13 mm) or greater than about 0.020″ (about 0.51 mm).
In some embodiments, the occluding function of the two-portion prosthetic mitral valve 400 can be performed using configurations other than a tri-leaflet occluder. For example, bi-leaflet, quad-leaflet, or mechanical valve constructs can be used in some embodiments.
As shown in
In some embodiments, the covering materials 270/340, or portions thereof, comprises a fluoropolymer, such as an expanded polytetrafluoroethylene (ePTFE) polymer. In some embodiments, the covering materials 270/340, or portions thereof, comprises a polyester, a silicone, a urethane, ELAST-EON™ (a silicone and urethane polymer), another biocompatible polymer, DACRON®, polyethylene terephthalate (PET), copolymers, or combinations and subcombinations thereof. In some embodiments, the covering materials 270/340, or portions thereof, comprises a biological tissue. For example, in some embodiments the covering materials 270/340 can include natural tissues such as, but not limited to, bovine, porcine, ovine, or equine pericardium. In some such embodiments, the tissues are chemically treated using glutaraldehyde, formaldehyde, or triglycidylamine (TGA) solutions, or other suitable tissue crosslinking agents.
In some embodiments, the anchor arches 250a, 250b, and 250c can include one or more covering-material cut-outs 252a, 252b, and 252c respectively. In some embodiments, the valve assembly portion 300 can include a fabric portion 314a (and fabric portions 314b and 314b; not visible) that are physically disposed within the covering-material cut-outs 252a, 252b, and 252c while the two-portion prosthetic mitral valve 400 is in its expanded configuration.
In some embodiments, the expandable frame structure of the anchor assembly portion 200 and/or the expandable frame structure of the valve assembly portion 300 are formed from a single piece of precursor material (e.g., sheet or tube) that is cut and expanded (and then connected to the hub 210 in the case of the anchor assembly 200). For example, some embodiments are fabricated from a tube that is laser-cut (or machined, chemically etched, water-jet cut, etc.) and then expanded and heat-set into its final expanded size and shape. In some embodiments, the expandable frame structure of the anchor assembly portion 200 is created compositely from multiple elongate members (e.g., wires or cut members) that are joined together with the hub 210 and each other to form the anchor assembly 200.
In some embodiments, the anchor assembly portion 200 and the valve assembly portion 300 can be conjoined or affixed to each other at particular locations of, or entirely along, the adjacent interfacing portions of the supra-annular ring 250 and the three atrial leaflet arches 310a, 310b, and 310c (undulating ring 310). For example, in some embodiments, solely discrete localized portions at the corresponding apices, or valleys, of the supra-annular ring 250 and the undulating ring 310 are attached/affixed to each other. Joining techniques such as, but not limited to, suturing, welding, using mechanical clips, lashing, and the like, and combinations thereof, can be used to attach/affix the supra-annular ring 250 and the undulating ring 310 (or discrete localized portions thereof) together. In certain embodiments, the apical portions and additional discrete localized portions along the adjacent interfacing supra-annular ring 250 and undulating ring 310 are attached/affixed to each other using such joining techniques. In particular embodiments, the supra-annular ring 250 and undulating ring 310 are attached/affixed to each other along the entire lengths thereof.
As an alternative to using the aforementioned joining techniques, in some embodiments, the frame structures of the anchor assembly portion 200 and the valve assembly portion 300 can be cut from a single piece of precursor material such that the frame structures are a unitary frame structure that comprises the frame structures of both the anchor assembly portion 200 and the valve assembly portion 300. In such a case, the supra-annular ring 250 and the three atrial leaflet arches 310a, 310b, and 310c (or particular portions thereof) are same physical elements (rather than being a conjoined two-piece construct that are attached/affixed to each other).
The expandable frame structures of the anchor assembly portion 200 and the valve assembly portion 300 can comprise various materials and combinations of materials. In some embodiments, nitinol (NiTi) is used as the material of the elongate members of the expandable frame structure of the anchor assembly portion 200 and/or the valve assembly portion 300, but other materials such as stainless steel, L605 steel, polymers, MP35N steel, stainless steels, titanium, cobalt/chromium alloy, polymeric materials, Pyhnox, Elgiloy, or any other appropriate biocompatible material, and combinations thereof can be used. The super-elastic properties of NiTi make it a particularly good candidate material for the elongate members of the expandable frame structure of the anchor assembly portion 200 and/or the valve assembly portion 300 because, for example, NiTi can be heat-set into a desired shape. That is, NiTi can be heat-set so that the anchor assembly portion 200 and/or the valve assembly portion 300 tends to self-expand into a desired shape when the anchor assembly portion 200 and/or the valve assembly portion 300 is unconstrained, such as when the anchor assembly portion 200 and/or the valve assembly portion 300 is deployed out from the anchor delivery sheath 130. An expandable frame structure of the anchor assembly portion 200 and/or the valve assembly portion 300 made of NiTi, for example, may have a spring nature that allows the anchor assembly portion 200 and/or the valve assembly portion 300 to be elastically collapsed or “crushed” to a low-profile delivery configuration and then to self-expand to the expanded configuration. The anchor assembly portion 200 and/or the valve assembly portion 300 may be generally conformable, fatigue resistant, and elastic to conform to the topography of the surrounding tissue when the anchor assembly portion 200 and/or the valve assembly portion 300 is deployed in the native mitral valve 17 of the patient 1.
Still referring to
In some embodiments, the anchor feet 220a, 220b, 220c, and 220d have a height ranging from about 8 mm to about 12 mm, or more than about 12 mm. In some embodiments, the anchor feet 220a, 220b, 220c, and 220d have a gutter engaging surface area (when fabric covered) ranging from about 6 mm2 to about 24 mm2. In some embodiments, the anchor feet 220a, 220b, 220c, and 220d each have essentially the same gutter engaging surface area. In particular embodiments, one or more of the anchor feet 220a, 220b, 220c, and 220d has a different gutter engaging surface area than one or more of the other anchor feet 220a, 220b, 220c, and 220d. The anchor feet 220a, 220b, 220c, and 220d can have widths ranging within about 1.5 mm to about 4.0 mm or more, and lengths ranging within about 3 mm to about 6 mm or more. The anchor feet 220a, 220b, 220c, and 220d are sized and shaped so that the anchor assembly portion 200 does not significantly impair the natural function of mitral valve chordae tendineae 40, the native mitral valve leaflets, and papillary muscles even after the anchor assembly portion 200 is anchored at the mitral valve site.
Referring to
In the depicted example embodiment of the two-portion prosthetic mitral valve 400, discrete localized portions of the supra-annular ring 250 and undulating ring 310 are attached/affixed to each other (rather than being attached/affixed to each other along the entire lengths thereof). In particular, in the depicted embodiment localized portions of the apices of the supra-annular ring 250 and undulating ring 310 are attached/affixed to each other (while no other portions thereof are attached/affixed). The attachment can be created using joining techniques as described above, or by forming the frame structures of the supra-annular ring 250 and undulating ring 310 from a common piece of precursor material such that the respective local apical portions are made of shared unitary material (e.g., the same portion of material acting as the apices of each of the supra-annular ring 250 and undulating ring 310).
Referring also to
In some implementations, a sheath 120 (which is a part of the transcatheter delivery system 100) can be used to simultaneously deliver the anchor assembly portion 200 and the valve assembly portion 300 to the heart 10. That is, the anchor assembly portion 200 and the valve assembly portion 300 can be elastically collapsed to reduced diameters and constrained within the confines of the low-profile sheath 120. In that arrangement, the sheath 120 (containing the anchor assembly portion 200 and the valve assembly portion 300 in radially collapsed configurations) can be navigated through the patient's vasculature and heart to arrive at the target location (e.g., within the heart proximate to the patient's native mitral valve). There, the anchor assembly portion 200 and the valve assembly portion 300 can be expressed out of the sheath 120.
In some embodiments the sheath 120 has an outer diameter of about 28 Fr (about 9.3 mm), or about 30 Fr (about 10.0 mm). In some embodiments, the sheath 120 has an outer diameter in the range of about 26 Fr to about 34 Fr (about 8.7 mm to about 11.3 mm). In some embodiments, the sheath 120 has an outer diameter in the range of about 20 Fr to about 28 Fr (about 6.7 mm to about 9.3 mm).
The transcatheter delivery system 100 can also include a delivery catheter 140. As described further below, the anchor assembly portion 200 and the valve assembly portion 300 can be attached to the delivery catheter 140 using one or more control wires. The delivery catheter 140 and the control wires can thereby be manipulated by a clinician to control the positioning of the anchor assembly portion 200 and the valve assembly portion 300 relative to the sheath 120. For example, the delivery catheter 140 can be pushed distally while the sheath 120 is held stationary to make the anchor assembly portion 200 and the valve assembly portion 300 emerge from within the sheath 120. Or, the sheath 120 can be pulled proximally while the delivery catheter 140 is held stationary to make the anchor assembly portion 200 and the valve assembly portion 300 emerge from within the sheath 120.
The transcatheter delivery system 100 can also include an inner catheter 160 (also referred to herein as a “pusher catheter 160”). In some implementations, the inner catheter 160 is releasably coupled with the hub 210 of the anchor assembly 200. For example, in some embodiments an externally threaded distal end portion of the inner catheter 160 can be threadedly coupled with an internally threaded hole defined by the hub 210. When the nested anchor assembly portion 200 and valve assembly portion 300 are expressed from the sheath 120, the inner catheter 160 can be moved (e.g., pushed distally) or held stationary in concert with the delivery catheter 140.
In some embodiments, components of the transcatheter delivery system 100 (such as the sheath 120, the delivery catheter 140, and/or the inner catheter 160) can include one or more of the following features. In some embodiments, one or more portions of the components of the transcatheter delivery system 100 are steerable (also referred to herein as “deflectable”). Using such steering, the transcatheter delivery system 100 can be deflected to navigate the patient's anatomy and/or to be positioned in relation to the patient's anatomy as desired. For example, the sheath 120 can be angled within the right atrium 12 to navigate the sheath 120 from the inferior vena cava 11 to the atrial septum. Accordingly, in some embodiments the sheath 120 may include at least one deflectable zone. Using a device such as the deployment control system 6 (
In some embodiments, the sheath 120, the delivery catheter 140, and/or the inner catheter 160 can comprise a tubular polymeric or metallic material. For example, in some embodiments the sheath 120, the delivery catheter 140, and/or the inner catheter 160 can be made from polymeric materials such as, but not limited to, polytetrafluoroethylene (PTFE), fluorinated ethylene propylene (FEP), HYTREL®, nylon, PICOFLEX®, PEBAX®, TECOFLEX®, and the like, and combinations thereof. In alternative embodiments, the sheath 120, the delivery catheter 140, and/or the inner catheter 160 can be made from metallic materials such as, but not limited to, nitinol, stainless steel, stainless steel alloys, titanium, titanium alloys, and the like, and combinations thereof. In some embodiments, the sheath 120, the delivery catheter 140, and/or the inner catheter 160 can be made from combinations of such polymeric and metallic materials (e.g., polymer layers with metal braid, coil reinforcement, stiffening members, and the like, and combinations thereof).
As stated above, in some embodiments one or more control wires can be used to releasably couple the anchor assembly portion 200 and the valve assembly portion 300 to the delivery catheter 140. Such control wires can also be used by a clinician to control the radial expansion of the anchor assembly portion 200 and the valve assembly portion 300—in some optional implementations, to control the radial expansion of the anchor assembly portion 200 independently from the radial expansion of the valve assembly portion 300 during the deployment procedure. For example, when a control wire is slackened (tension is relaxed) the associated anchor assembly portion 200 or valve assembly portion 300 will be allowed to radially self-expand. Conversely, when a control wire is tensioned, the associated anchor assembly portion 200 or valve assembly portion 300 will be radially contracted, compressed, or constrained. The control wires may also be thought of as “lassos” because, like a lasso, the control wires function to circumferentially, radially, or diametrically control/constrain the anchor assembly portion 200 and the valve assembly portion 300.
Still referring to
In some cases, a single control wire is coupled to only one of either the anchor assembly portion 200 or the valve assembly portion 300. In some such cases, a first control wire can be coupled to one region of either the anchor assembly portion 200 or the valve assembly portion 300, and a second control wire can be coupled to another region of same anchor assembly portion 200 or valve assembly portion 300.
In the depicted embodiment, the anchor assembly portion 200 and the valve assembly portion 300 are jointly configured to be releasably coupled with a proximal end control wire 142 at one or more proximal end coupling sites 254 that are located at, or adjacent to, the three apices of the supra-annular ring 250 and undulating ring 310. In addition, the anchor assembly portion 200 is configured to be releasably coupled with a mid-body region control wire 148 at one or more anchor assembly mid-body coupling sites 256. In addition, the valve assembly portion 300 is configured to be releasably coupled with a distal end region control wire 144 at one or more valve assembly distal end coupling sites 326.
The control wire coupling sites (e.g., the proximal end coupling sites 254, the anchor assembly mid-body coupling sites 256, and the valve assembly distal end coupling sites 326) can be various types of structures to which a wire can be releasably coupled. For example, in some embodiments the control wire coupling sites can be a loop of suture material, two loops of suture material, or three or more loops of suture material. In some embodiments, the control wire coupling sites can be a structure defining an eyelet formed by, or attached to, the framework of the anchor assembly portion 200 and/or the valve assembly portion 300. In some embodiments, the control wire coupling sites can be cells or struts of the framework of the anchor assembly portion 200 and/or the valve assembly portion 300. Other types of suitable control wire coupling sites can also be used.
In the depicted embodiment, the valve assembly portion 300 is coupled to the delivery catheter 140 by: (i) the proximal end control wire 142 and (ii) the valve assembly distal end control wire 144. The proximal end control wire 142 can be releasably coupled with the proximal end coupling sites 254. The valve assembly distal end control wire 144 can be releasably coupled with the valve assembly distal end coupling sites 326.
In the depicted embodiment, the anchor assembly portion 200 is coupled to the delivery catheter 140 by: (i) the proximal end control wire 142 and (ii) the anchor assembly mid-body control wire 148. The proximal end control wire 142 can be releasably coupled with the proximal end coupling sites 254. The anchor assembly mid-body control wire 148 can be releasably coupled with the anchor assembly mid-body coupling sites 256.
In some implementations, a deployment control handle/system (such as the deployment frame system 6 of
In some embodiments, the control wires extend through lumens defined in the wall of a catheter, such as the delivery catheter 140. The control wires can extend from such lumens through luminal orifices at the end of the catheter, or at non-end luminal orifice locations along the catheter. For example, in the depicted embodiment, the valve assembly distal end control wire 144 extends from luminal orifices at the end of the delivery catheter 140. However, the proximal end control wire 142 and the anchor assembly mid-body control wire 148 each extend from non-end luminal orifices located along the delivery catheter 140.
In some embodiments, such as the depicted embodiment, individual control wires form a loop at the end of the catheter (e.g., the delivery catheter 140). That is, the control wire exits from a first luminal orifice of the catheter, then loops through one or more attachment sites of the anchor assembly portion 200 and/or the valve assembly portion 300, then reenters a second luminal orifice of the catheter. Portions of the control wire are slidably positioned within lumens within the wall of the catheter. The two terminal ends of the control wire can be positioned at the user control mechanism (e.g., the deployment frame system 6 of
It should be understood that retrieval of the anchor assembly portion 200 and the valve assembly portion 300 can be readily performed at any time during the depicted sequential procedures as long as at least one of the control wires remains coupled to the anchor assembly portion 200 and/or valve assembly portion 300. For example, as long as the proximal end control wire 142 is coupled with the proximal ends of the anchor assembly portion 200 and the valve assembly portion 300, retrieval can be performed, for example, using the following procedure. The anchor assembly mid-body control wire 148 can be released and/or removed from engagement with the anchor assembly 200. Then, the valve assembly distal end control wire 144 can be tensioned to collapse the distal end of the valve assembly portion 300. Next, the proximal end control wire 142 that is shared by the proximal ends of the anchor assembly portion 200 and the valve assembly portion 300 can be tensioned to collapse the proximal end of the anchor assembly portion 200 and the valve assembly portion 300 such that retrieval features (e.g., hooks, clips, slots, etc.) on the delivery catheter 140 become engaged with the framework of the anchor assembly portion 200 and/or valve assembly portion 300. Next, the anchor assembly portion 200 and the valve assembly portion 300 can be retracted into sheath 120 (e.g., by pulling the delivery catheter 140 proximally in relation to the sheath 120). The retrieval features on the delivery catheter 140 (with which the anchor assembly portion 200 and/or the valve assembly portion 300 are engaged) and the tensioned valve assembly distal end control wire 144 facilitate the insertion of the valve assembly portion 300 (along with the delivery catheter 140) into the sheath 120.
Referring to
After the two-portion prosthetic mitral valve 400 is expressed from the sheath 120 in the left atrium 16, a clinician can relax some tension from the anchor assembly mid-body control wire 148 to allow the anchor assembly portion 200 to partially expand. For example, in some cases the mid-body region of the anchor assembly portion 200 may be allowed to expand about 75% of its fully expanded radial size. Accordingly, the anchor feet 220a, 220b, 220c, and 220d (
With the mid-body region of the anchor assembly portion 200 partially expanded, the nested anchor assembly portion 200 and valve assembly portion 300 can be pushed distally (inferiorly toward the left ventricle 18) as indicated by arrow 50. The anchor feet 220a, 220b, 220c, and 220d may physically help to proper align the anchor assembly portion 200 (and the two-portion prosthetic mitral valve 400 as a whole) to the native mitral valve 17 as the anchor assembly portion 200 is partially pushed through the annulus of the native mitral valve 17. The distal portions of the nested anchor assembly portion 200 and valve assembly portion 300 will pass through the annulus of the native mitral valve 17 and into the left ventricle 18 as shown. With the anchor assembly portion 200 partially radially contracted in a desired orientation, and appropriately aligned with the native mitral valve 17, the anchor assembly portion 200 can be safely passed through the native mitral valve 17 without damaging the native mitral valve 17 and/or entangling chordae tendineae of the native mitral valve 17.
Referring to
The regions at or near the high collagen annular trigones of the sub-annular gutter 19 can generally be relied upon to provide strong, stable anchoring locations. The muscle tissue in the regions at or near the trigones also provides a good tissue ingrowth substrate for added stability and migration resistance of the anchor assembly 200. Therefore, the regions at or near the trigones define a left anterior anchor zone and a right anterior anchor zone. The left anterior anchor zone and the right anterior anchor zone provide advantageous target locations for placement of the lateral anterior foot 220a and the medial anterior foot 220d respectively. The left posterior anchor zone and the right anterior anchor zone of the sub-annular gutter 19 can receive the lateral posterior foot 220b and the medial posterior foot 220c respectively.
Referring to
With the tensions from the proximal end control wire 142 and the anchor assembly mid-body control wire 148 removed, the anchor assembly portion 200 is fully expanded and engaged with the native mitral valve 17. Thereafter, the clinician can remove the proximal end control wire 142 and the anchor assembly mid-body control wire 148 from engagement with the two-portion prosthetic mitral valve 400 if so desired. To do so, the clinician can simply pull on a first end of the control wire 142 and/or 148 while the second end of the control wire 142 and/or 148 is free to move.
Referring to
The anchor assembly portion 200 is already deployed at this stage (other than the continued releasable coupling of the inner catheter 160 to the hub 210 of the anchor assembly 200). To allow the valve assembly portion 300 to fully radially expand while being nested within the anchor assembly 200, the tension of the valve assembly distal end control wire 144 can be relaxed. Relaxing tension from the valve assembly distal end control wire 144 allows the valve assembly portion 300 to self-expand and to couple with the anchor assembly 200.
In some cases, the tensions of the proximal end control wire 142 and the valve assembly distal end control wire 144 can be relaxed simultaneously. In some cases, the tensions of the proximal end control wire 142 and the valve assembly distal end control wire 144 can be relaxed serially (including any and all possible patterns of alternating, step-wise, and partial relaxations of the tensions).
When the valve assembly portion 300 and the anchor assembly portion 200 are coupled together, the valve assembly portion 300 is geometrically interlocked within the interior space of the anchor assembly portion 200 (e.g., in some embodiments by virtue of the tapered shape of the valve assembly portion 300 within the supra-annular ring and interior space of the anchor assembly 200). In particular, in some embodiments the valve assembly portion 300 is contained within the interior space between the supra-annular ring 250 and the sub-annular support arms 230a, 230b, 230c, and 230d (refer to
The next step of the process for deploying the two-portion prosthetic mitral valve 400 can include removal of the valve assembly distal end control wire 144 from engagement with the valve assembly distal end coupling sites 326. The removal of the valve assembly distal end control wire 144 can be performed as described above in reference to the proximal end control wire 142 and the anchor assembly mid-body control wire 148.
After the valve assembly portion 300 has been expanded into a coupled relationship with the anchor assembly 200, the clinician can verify that the anchor assembly portion 200 and the valve assembly portion 300 are in the desired positions. Additionally, the clinician may verify other aspects such as, but not limited to, the hemodynamic performance and sealing of the anchor assembly portion 200 and the valve assembly portion 300.
The anchor assembly portion 200 and the valve assembly portion 300 of the two-portion prosthetic mitral valve 400 are deployed at this stage (other than the continued releasable coupling of the inner catheter 160 to the hub 210 of the anchor assembly 200).
The process of deploying the two-portion prosthetic mitral valve 400 arranged in the nested configuration can be completed by disengaging the inner catheter 160 from the hub 210 of the anchor assembly 200, and removing the delivery system 100 from the patient. The SAM containment member 212 (
While the components of the delivery system 100 and the two-portion prosthetic mitral valve 400 are depicted in particular relative orientations and arrangements, it should be understood that the depictions are non-limiting.
Referring to
In this example that uses only the two control wires 142 and 144, the relative positioning of the inner catheter 160 (coupled to the hub 210) compared to the delivery catheter 140 can be adjusted to control the radial expansion of the mid-body of the anchor assembly 210 (and to control of the positions of the anchor feet 220a, 220b, 220c, and 220d relative to the sub-annular gutter 19, as shown in
Referring to
Referring to
In the depicted example embodiment of the two-portion prosthetic mitral valve 400, the entireties of the supra-annular ring 250 and undulating ring 310 are attached/affixed to each other (rather than being attached/affixed to each other at discrete localized portions at the apices thereof as described above). In some embodiments, the entireties of the supra-annular ring 250 and undulating ring 310 can be attached/affixed using joining techniques as described above, or by forming the frame structures of the supra-annular ring 250 and undulating ring 310 from a common piece of precursor material such that the supra-annular ring 250 and undulating ring 310 are made of shared unitary material (e.g., the same portion of material acting as the supra-annular ring 250 and undulating ring 310).
Alternatively, the example two-portion prosthetic mitral valve 400 depicted here can have just localized portions of the valleys of the supra-annular ring 250 and undulating ring 310 attached/affixed to each other (such as at valley portion 251), while the apices and other portions of the supra-annular ring 250 and undulating ring 310 are not attached/affixed to each other.
Referring also to
In some implementations, the sheath 120 (which is a part of the transcatheter delivery system 100 as described above) can be used to simultaneously deliver the anchor assembly portion 200 and the valve assembly portion 300 to the heart 10. That is, the anchor assembly portion 200 and the valve assembly portion 300 can be elastically collapsed to reduced diameters and constrained within the confines of the low-profile sheath 120. In that arrangement, the sheath 120 (containing the anchor assembly portion 200 and the valve assembly portion 300 in radially collapsed configurations) can be navigated through the patient's vasculature and heart to arrive at the target location (e.g., within the heart proximate to the patient's native mitral valve). There, the anchor assembly portion 200 and the valve assembly portion 300 can be expressed out of the sheath 120.
The transcatheter delivery system 100 can also include the inner catheter 160 (also referred to herein as a “pusher catheter 160”) that can be releasably coupled with the hub 210 of the anchor assembly 200. The transcatheter delivery system 100 can also include the delivery catheter 140. As stated above, in some embodiments one or more control wires can be used to releasably couple the anchor assembly portion 200 and the valve assembly portion 300 to the delivery catheter 140. Such control wires can also be used by a clinician to control the radial expansion of the anchor assembly portion 200 and the valve assembly portion 300—in some optional implementations, to control the radial expansion of the anchor assembly portion 200 independently from the radial expansion of the valve assembly portion 300 during the deployment procedure.
Still referring to
In some cases, a single control wire is coupled to only one of either the anchor assembly portion 200 or the valve assembly portion 300. In some such cases, a first control wire can be coupled to one region of either the anchor assembly portion 200 or the valve assembly portion 300, and a second control wire can be coupled to another region of same anchor assembly portion 200 or valve assembly portion 300.
In the depicted embodiment, the anchor assembly portion 200 and the valve assembly portion 300 are jointly configured to be releasably coupled with a proximal end control wire 142 at one or more proximal end coupling sites 254 that are located at, or adjacent to, the three apices of the supra-annular ring 250 and undulating ring 310. In addition, the anchor assembly portion 200 and the valve assembly portion 300 are jointly configured to be releasably coupled with a mid-body region control wire 148 at one or more mid-body coupling sites 256 that are located at, or adjacent to, the three valleys of the supra-annular ring 250 and undulating ring 310. In addition, the valve assembly portion 300 is configured to be releasably coupled with a distal end region control wire 144 at one or more valve assembly distal end coupling sites 326.
The control wire coupling sites (e.g., the proximal end coupling sites 254, the mid-body coupling sites 256, and the valve assembly distal end coupling sites 326) can be various types of structures to which a wire can be releasably coupled. For example, in some embodiments the control wire coupling sites can be a loop of suture material, two loops of suture material, or three or more loops of suture material. In some embodiments, the control wire coupling sites can be a structure defining an eyelet formed by, or attached to, the framework of the anchor assembly portion 200 and/or the valve assembly portion 300. In some embodiments, the control wire coupling sites can be cells or struts of the framework of the anchor assembly portion 200 and/or the valve assembly portion 300. Other types of suitable control wire coupling sites can also be used.
In the depicted embodiment, the valve assembly portion 300 is coupled to the delivery catheter 140 by: (i) the proximal end control wire 142, (ii) the mid-body control wire 148, and (iii) the valve assembly distal end control wire 144. The proximal end control wire 142 can be releasably coupled with the proximal end coupling sites 254. The mid-body control wire 148 can be releasably coupled with the mid-body coupling sites 256. The valve assembly distal end control wire 144 can be releasably coupled with the valve assembly distal end coupling sites 326.
In the depicted embodiment, the anchor assembly portion 200 is coupled to the delivery catheter 140 by: (i) the proximal end control wire 142 and (ii) the mid-body control wire 148. The proximal end control wire 142 can be releasably coupled with the proximal end coupling sites 254. The mid-body control wire 148 can be releasably coupled with the mid-body coupling sites 256.
In some implementations, a deployment control handle/system (such as the deployment frame system 6 of
It should be understood that retrieval of the anchor assembly portion 200 and the valve assembly portion 300 can be readily performed at any time during the depicted sequential procedures as long as at least one of the control wires remains coupled to the anchor assembly portion 200 and/or valve assembly portion 300. For example, as long as the proximal end control wire 142 is coupled with the proximal ends of the anchor assembly portion 200 and the valve assembly portion 300, retrieval can be performed, for example, using the following procedure. The mid-body control wire 148 can be released and/or removed from engagement with the anchor assembly 200. Then, the valve assembly distal end control wire 144 can be tensioned to collapse the distal end of the valve assembly portion 300. Next, the proximal end control wire 142 that is shared by the proximal ends of the anchor assembly portion 200 and the valve assembly portion 300 can be tensioned to collapse the proximal end of the anchor assembly portion 200 and the valve assembly portion 300 such that retrieval features (e.g., hooks, clips, slots, etc.) on the delivery catheter 140 become engaged with the framework of the anchor assembly portion 200 and/or valve assembly portion 300. Next, the anchor assembly portion 200 and the valve assembly portion 300 can be retracted into sheath 120 (e.g., by pulling the delivery catheter 140 proximally in relation to the sheath 120). The retrieval features on the delivery catheter 140 (with which the anchor assembly portion 200 and/or the valve assembly portion 300 are engaged) and the tensioned valve assembly distal end control wire 144 facilitate the insertion of the valve assembly portion 300 (along with the delivery catheter 140) into the sheath 120.
Referring to
After the two-portion prosthetic mitral valve 400 is expressed from the sheath 120 in the left atrium 16, a clinician can relax some tension from the mid-body control wire 148 to allow the anchor assembly portion 200 to partially expand. For example, in some cases the mid-body region of the anchor assembly portion 200 may be allowed to expand about 75% of its fully expanded radial size. Accordingly, the anchor feet 220a, 220b, 220c, and 220d (
With the mid-body region of the anchor assembly portion 200 partially expanded, the nested anchor assembly portion 200 and valve assembly portion 300 can be pushed distally (inferiorly toward the left ventricle 18) as indicated by arrow 50. The anchor feet 220a, 220b, 220c, and 220d may physically help to proper align the anchor assembly portion 200 (and the two-portion prosthetic mitral valve 400 as a whole) to the native mitral valve 17 as the anchor assembly portion 200 is partially pushed through the annulus of the native mitral valve 17. The distal portions of the nested anchor assembly portion 200 and valve assembly portion 300 will pass through the annulus of the native mitral valve 17 and into the left ventricle 18 as shown. With the anchor assembly portion 200 partially radially contracted in a desired orientation, and appropriately aligned with the native mitral valve 17, the anchor assembly portion 200 can be safely passed through the native mitral valve 17 without damaging the native mitral valve 17 and/or entangling chordae tendineae of the native mitral valve 17.
Referring to
Referring to
With the tensions from the proximal end control wire 142 and the mid-body control wire 148 removed, the anchor assembly portion 200 is fully expanded and engaged with the native mitral valve 17. Thereafter, the clinician can remove the proximal end control wire 142 and the mid-body control wire 148 from engagement with the two-portion prosthetic mitral valve 400 if so desired. To do so, the clinician can simply pull on a first end of the control wire 142 and/or 148 while the second end of the control wire 142 and/or 148 is free to move.
Referring to
The anchor assembly portion 200 is already deployed at this stage (other than the continued releasable coupling of the inner catheter 160 to the hub 210 of the anchor assembly 200). To allow the valve assembly portion 300 to fully radially expand while being nested within the anchor assembly 200, the tension of the valve assembly distal end control wire 144 can be relaxed. Relaxing tension from the valve assembly distal end control wire 144 allows the valve assembly portion 300 to self-expand and to couple with the anchor assembly 200.
In some cases, the tensions of the proximal end control wire 142 and the valve assembly distal end control wire 144 can be relaxed simultaneously. In some cases, the tensions of the proximal end control wire 142 and the valve assembly distal end control wire 144 can be relaxed serially (including any and all possible patterns of alternating, step-wise, and partial relaxations of the tensions).
When the valve assembly portion 300 and the anchor assembly portion 200 are coupled together, the valve assembly portion 300 is geometrically interlocked within the interior space of the anchor assembly portion 200. In particular, in some embodiments the valve assembly portion 300 is contained within the interior space between the supra-annular ring 250 and the sub-annular support arms 230a, 230b, 230c, and 230d (refer to
The next step of the process for deploying the two-portion prosthetic mitral valve 400 can include removal of the valve assembly distal end control wire 144 from engagement with the valve assembly distal end coupling sites 326. The removal of the valve assembly distal end control wire 144 can be performed as described above in reference to the proximal end control wire 142 and the mid-body control wire 148.
After the valve assembly portion 300 has been expanded into a coupled relationship with the anchor assembly 200, the clinician can verify that the anchor assembly portion 200 and the valve assembly portion 300 are in the desired positions. Additionally, the clinician may verify other aspects such as, but not limited to, the hemodynamic performance and sealing of the anchor assembly portion 200 and the valve assembly portion 300.
The anchor assembly portion 200 and the valve assembly portion 300 of the two-portion prosthetic mitral valve 400 are deployed at this stage (other than the continued releasable coupling of the inner catheter 160 to the hub 210 of the anchor assembly 200).
The process of deploying the two-portion prosthetic mitral valve 400 arranged in the nested configuration can be completed by disengaging the inner catheter 160 from the hub 210 of the anchor assembly 200, and removing the delivery system 100 from the patient. The SAM containment member 212 (
While the components of the delivery system 100 and the two-portion prosthetic mitral valve 400 are depicted in particular relative orientations and arrangements, it should be understood that the depictions are non-limiting.
Referring to
In this example that uses only the two control wires 142 and 144, the relative positioning of the inner catheter 160 (coupled to the hub 210) compared to the delivery catheter 140 can be adjusted to control the radial expansion of the mid-body of the anchor assembly 210 (and to control of the positions of the anchor feet 220a, 220b, 220c, and 220d relative to the sub-annular gutter 19, as shown in
Referring to
A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the scope of the invention. Accordingly, other embodiments are within the scope of the following claims.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2020/033631 | 5/19/2020 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62850110 | May 2019 | US |
